Last reviewed · How we verify
Luliconazole Cream 1%
Luliconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
Luliconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis in fungal cell membranes. Used for Tinea corporis (ringworm of the body), Tinea cruris (jock itch), Tinea pedis (athlete's foot).
At a glance
| Generic name | Luliconazole Cream 1% |
|---|---|
| Also known as | Product 33525, LUZU Cream 1% |
| Sponsor | Bausch Health Americas, Inc. |
| Drug class | Imidazole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
As an imidazole antifungal, luliconazole blocks the cytochrome P450-dependent enzyme lanosterol 14α-demethylase, which is essential for converting lanosterol to ergosterol in fungi. This disruption of ergosterol biosynthesis compromises the integrity and permeability of the fungal cell membrane, leading to cell death. The topical cream formulation delivers high local concentrations to affected skin.
Approved indications
- Tinea pedis (athlete's foot)
- Tinea cruris (jock itch)
- Tinea corporis (ringworm)
Common side effects
- Application site irritation
- Application site erythema
- Contact dermatitis
Key clinical trials
- Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor. (PHASE4)
- Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris (PHASE4)
- Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris (PHASE4)
- Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis (PHASE4)
- Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Luliconazole Cream 1% CI brief — competitive landscape report
- Luliconazole Cream 1% updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI